Half-dose photodynamic therapy versus 577 nm subthreshold pulse laser therapy in treatment-naive patients with central serous chorioretinopathy

Table 1 Demographics

	HD-PDT	SPL	P-Value
Number of patients, n (%)	49 (51.6)	46 (48.4)
Age (years), median (IQR)	51.0 (45.5–57.5)	47 (42.3–55.0)	0.119
Male sex, n (%)	32/49 (65.3)	36/46 (78.3)	0.162
Disease duration (years), median (IQR)	0.59 (0.32–1.56)	0.96 (0.35–3.09)	0.288
Complex CSC subclassification, n (%)	25 (51.0)	28 (60.9)	0.334
Steroid use within last 3 months, n (%)	5/46 (10.9)^*	7/40 (17.5)^*	0.376
Affected fellow eye, n (%)	25/49 (51.0)	27/46 (58.7)	0.453
Hypertension, n (%)	10/49 (20.4)	13/46 (28.3)	0.372
Hotspot on ICGA, n (%)	27/44 (61.4)^†	34/43 (79.1)^†	0.071
BCVA (logMAR), median (IQR)	0.2 (0.2–0.4)	0.2 (0.2–0.4)	0.527
CRT (µm), mean ± SD	416.1 ± 122.9	423.2 ± 117.4	0.445
SRF/PR (µm), mean ± SD	256.5 ± 113.3	256.7 ± 114.0	0.973

Legend: Pearson’s chi² test for categorical variables; Mann-Whitney U Test for continuous variables. *Missing data Steroid use within 3 months: 3 cases in half dose PDT group, 6 cases in SPL group. †Missing data Hotspot on ICG-A: 5 cases in half dose PDT group, 3 cases in SPL group. BCVA: Best corrected visual acuity, CRT: Central retinal thickness, ICGA: Indocyanine green angiography, IQR: Interquartilrange (IQ percentile 25%- IQ percentile 75%), HD-PDT: Half-Dose photodynamic therapy, OD: Optic disc diameter, PR: Photoreceptors, SD: Standard deviation, SPL: Subthreshold pulse laser, SRF: Subretinal fluid

ISSN: 1471-2415